论文部分内容阅读
目的对比酚妥拉明与硝普钠治疗冠心病心力衰竭的临床疗效。方法 80例冠心病心力衰竭患者,按照治疗方法不同分为A组(37例)和B组(43例)。A组患者给予硝普钠治疗,B组患者给予酚妥拉明治疗,比较两组疗效。结果 A组患者总缓解36例(97.3%);B组患者总缓解35例(81.4%),A组总缓解率明显高于B组,差异具有统计学意义(P<0.05)。治疗前两组患者左室舒张末内径(LVEDD)、左室射血分数(LVEF)、左室收缩末内径(LVESD)比较差异无统计学意义(P>0.05);两组患者治疗后LVEDD、LVEF、LVESD较治疗前改善显著(P<0.05),治疗后A组患者LVEDD为(56.14±3.35)mm、LVEF为(47.05±6.70)%、LVESD为(36.70±4.25)mm,改善状况明显优于B组的(59.87±7.76)mm、(37.22±5.55)%、(40.35±4.32)mm,差异具有统计学意义(P<0.05)。结论硝普钠治疗心力衰竭无论从症状改善还是心功能相关指标改善方面均优于酚妥拉明,安全性高,值得在临床治疗中广泛推广。
Objective To compare the clinical efficacy of phentolamine and sodium nitroprusside in the treatment of heart failure with coronary heart disease. Methods Eighty patients with heart failure and coronary heart disease were divided into group A (n = 37) and group B (n = 43) according to the different treatment methods. Patients in group A received sodium nitroprusside, while patients in group B received phentolamine. The efficacy of the two groups was compared. Results A total of 36 patients (97.3%) were relieved in group A; 35 patients (81.4%) were relieved in group B, the total remission rate in group A was significantly higher than that in group B, the difference was statistically significant (P <0.05). LVEDD, LVEF and LVESD in the two groups before treatment were not significantly different (P> 0.05). After treatment, LVEDD, LVEDD, LVEF and LVESD improved significantly (P <0.05). After treatment, the LVEDD of group A was (56.14 ± 3.35) mm, the LVEF was (47.05 ± 6.70)% and the LVESD was (36.70 ± 4.25) mm (59.87 ± 7.76) mm, (37.22 ± 5.55)%, (40.35 ± 4.32) mm in group B, the difference was statistically significant (P <0.05). Conclusion Sodium nitroprusside is superior to phentolamine in improving heart failure symptoms and improving symptoms of heart failure. It is safe and should be widely used in clinical treatment.